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STATEMENT OF TRANSLATIONAL RELEVENCE

Conclusion:
Certain aggressive B-cell lymphomas and virus-and immunodeficiencyassociated malignancies associated with an ineffective T-cell immune response express PD-L1 on tumor cells and infiltrating macrophages. These results identify a group of neoplasms that should be considered for PD-1/PD-L1-directed therapies, and validate methods to detect PD-L1 in FFPE tissue biopsies.
INTRODUCTION
Programmed cell death ligand 1 (PD-L1, also known as B7-H1) is an immunomodulatory cell-surface glycoprotein and a member of the B7 family of costimulatory molecules primarily expressed by antigen-presenting cells and that serve to regulate the cellular immune response. 1 Binding of PD-L1 to its cognate receptor PD-1 inhibits proliferation of activated T cells in peripheral tissues leading to "T-cell exhaustion," a functional phenotype that can be reversed by PD-1 blockade. 2 In clinical trials of anti-PD-1 and anti-PD-L1 antibodies, patients with solid tumors have achieved long-lasting clinical responses and thus emphasizing the importance of the PD-1/PD-L1 axis in regulating anti-tumor immunity. 3, 4 Moreover, in the limited number of cases examined, clinical responsiveness to PD-1 blockade correlated with tumor-cell specific expression of PD-L1 as detected by immunohistochemistry (IHC) using a proprietary antibody. 4 We have shown that Hodgkin lymphoma cell lines express high levels of PD-L1 transcript and protein due to multiple mechanisms including genetic amplification of CD274 (encoding PD-L1) and constitutive AP1 signaling. Hodgkin cell lines show variable copy number gain of chromosome 9p24.1, a genomic region that includes CD274 (encoding PD-L1), PDCD1LG2 (encoding PD-L2), and JAK2. 5 The copy number of 9p24.1 correlates with cell surface PD-L1 protein expression due to direct amplification of CD274, and to increased JAK2 protein expression, enhanced JAK-STAT signaling, and activation of an interferon (IFN)-stimulated regulatory element/IFNregulatory factor 1 (ISRE/IRF1) motif in the CD274 promoter. 6, 7 In a series of genetically annotated primary classical Hodgkin lymphoma (CHL) cases, we found that high copy numbers of 9p24.1 correlated with increased PD-L1 expression in ReedSternberg (RS) cells. 5 We have further shown that: 1) PD-L1 expression is regulated by an AP1-dependent enhancer in CD274; 2) AP1 signaling components JunB/cJun constitutively bind this enhancer in Hodgkin lines; and 3) JunB and cJun are overexpressed in primary RS cells. 5 Moreover, a subset of CHL is Epstein-Barr virus (EBV)-positive and aberrant signaling through EBV-encoded gene products provides alternative mechanisms to upregulate PD-L1. In a genetically annotated series of primary CHL we found that 9p24.1 amplification and EBV-infection were mutually exclusive. Using EBV-transformed B cells, we demonstrated that the expression of the EBV-encoded latent membrane protein (LMP)-1 promotes both AP1-signaling and JAK-STAT signaling to activate the enhancer and promoter elements of CD274, respectively. 6 Consistent with these findings, we have detected PD-L1 in the majority of examined EBV-positive post-transplant lymphoproliferative disorders (PTLD). 6 Our studies indicate that CHL and EBV-positive PTLD utilize several complementary mechanisms to upregulate PD-L1 in tumor cells.
CHL is also notable for its prominent inflammatory infiltrate which includes a skewed Tcell population and abundant macrophages. In CHL, increased numbers of CD68+ tumor-associated macrophages have been associated with inferior clinical outcome. 8, 9 However, the biological basis for this association remains undefined.
CHL is genetically, phenotypically, and/or histologically related to additional large cell lymphomas including primary mediastinal large B-cell lymphoma (PMLBCL), nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), and T-cell rich, histiocyte-rich large B-cell lymphoma (TCRLBCL). 10, 11 Similarly, EBV and the closely related virus human herpes virus-8 (HHV8, also known as Kaposi sarcoma-associated herpesvirus) are postulated or known drivers of additional malignancies that include HIV/immunodeficiency-related diffuse large B-cell lymphoma (DLBCL), EBVassociated DLBCL of the elderly, extranodal NK/T cell lymphoma (ENKTCL), nasopharyngeal carcinoma (NPC), plasmablastic lymphoma (PBL), endemic Burkitt lymphoma (BL), and the HHV8-associated primary effusion lymphoma (PEL) and Kaposi sarcoma (KS). 12, 13 A comprehensive analysis of PD-L1 expression in these tumor types has not been completed.
In this study, we validate two novel anti-PD-L1 antibodies for the detection of PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) tissue sections. We then evaluate PD-L1 expression in a range of aggressive lymphoid malignancies, including those related to CHL and those associated with EBV and/or HHV8 infection, as well as NPC and KS. We find that robust expression of PD-L1 is characteristic of the malignant cells and a large proportion of non-malignant cells, primarily tumor infiltrating macrophages, within the tumor microenvironment of CHL, PMLBCL, TCRLBCL, and a broad range of virus-and immunodeficiency-associated malignancies that are characterized by an ineffective immune response. Our results further provide a biological basis for the prognostic significance of tumor-infiltrating macrophages. Finally, our methods establish a template for screening FFPE tumor biopsies for PD-L1 expression by IHC using a generally available monoclonal antibody.
MATERIALS AND METHODS
Case Selection
Cases were retrieved from the surgical pathology files of Brigham and Women's cases of ENKTCL, and 7 of 9 cases of PBL were shown previously to be positive for EBV-encoded RNA (EBER) by in situ hybridization study. All EBV-negative PTLD and DLBCL-NOS cases were negative for EBER. All PEL and KS cases were shown previously to be positive for HHV8 by immunohistochemistry.
Cell culture and Western blot
Hodgkin lymphoma cell lines (L428, SUP-HD1, and HDLM2) and DLBCL cell lines (SUDHL4 and OCI-Ly1) were cultured as previously described. Cruz) in 3% non-fat dry milk.
Immunohistochemistry
IHC using a rabbit anti-PD-L1 monoclonal antibody (clone 15, #10084-R015, 6.2ug/ml final concentration, Sino Biological, Beijing, China) was performed using 4-μm-thick, FFPE tissue sections on a Benchmark XT autostainer (Ventana Medical System, Tuscon, AZ) with standard antigen retrieval methods (CC1 buffer, pH8.0, #950-124, Ventana).
UltraView Universal DAB Detection kit (#760-500, Ventana) was used according to the manufacturer's instructions. Counterstaining was performed as part of the automated staining protocol using hematoxylin (#760-2021, Ventana). IHC using the mouse anti-PD-L1 monoclonal antibody (IgG1, generated in the laboratory of G. Freeman, clone 339.7G11, 69 ug/ml final concentration) was performed using the same protocol as above. After staining, slides were then washed in soap water and distilled water, dehydrated in graded alcohol and xylene, mounted and coverslipped. The protocols for double IHC staining are available in Supplementary Methods.
Case Evaluation
All IHC stained sections were initially evaluated and scored by a hematopathologist of the total tissue cellularity showed 2+ or 3+ membrane or cytoplasmic staining in malignant and/or non-malignant cells. The threshold for positive PD-L1 staining in malignant cells used here is comparable to that used in prior publications, using a distinct antibody. 4, 15, 16 Appropriate external positive (placenta) and negative (tonsil) controls were also included with each staining run.
RESULTS
Validation of PD-L1 antibodies for IHC.
After testing a variety of commercially available antibodies, we identified a rabbit monoclonal antibody that demonstrated both sensitive and specific staining for PD-L1 on a set of well-characterized cell lines and tissues ( Importantly, no band was detected in lysates derived from DLBCL cell lines (SUDHL4, OCI-Ly1), consistent with the previously reported lack of detectable PD-L1 in these lines ( Figure   1A ). 5 Similarly, IHC analysis of FFPE cell pellets using the rabbit monoclonal antibody revealed robust staining of the Hodgkin cell line HDLM2 in a strong membranous pattern ( Figure 1B) but not in the DLBCL line SUDHL4 ( Figure 1C ). The staining pattern was identical using the mouse monoclonal antibody ( Figures 1B and 1C insets) . Additional IHC analysis of transfected cell lines showed specific staining by both rabbit and mouse PD-L1 antibodies of cell lines expressing human PD-L1 but not human PD-L2 (data not shown). We conclude that IHC analysis using both the rabbit and mouse monoclonal antibodies is specific for PD-L1 protein.
IHC analysis of human tonsil revealed little to no specific staining of the vast majority of lymphocytes within the interfollicular T cell-rich regions and in the B cell-rich secondary follicles using the rabbit monoclonal PD-L1 antibody ( Figure 1D ). Rare lymphoid cells within reactive germinal centers did show weak membranous staining. High-power examination of human tonsil also revealed distinct membranous staining of the tonsilar epithelium and weak, membranous staining of scattered cells morphologically consistent with macrophages ( Figure 1D inset). 1, 16 IHC analysis of tonsil using the mouse monoclonal PD-L1 antibody resulted in identical findings (Supplemental Figure S1 ). As an external positive control, syncytiotrophoblasts in human placental tissue demonstrated strong membranous expression of PD-L1, as described previously (Supplemental Figure   S1 ). 1 We noted that with the rabbit monoclonal antibody, a mild degree of general, nonspecific background staining was observed in tissue sections. Background staining varied according to the degree of dilution necessary to achieve the final antibody concentration optimized for IHC (Supplemental Figure S1 ). Less background was associated with the more concentrated lots of antibody (6.2 ug/ml final concentration used; lot concentrations ranged from 0.22 to 1.55 mg/ml). Very little background was noted with the mouse monoclonal antibody (Supplemental Figure S1 ; S2).
Expression of PD-L1 in HL and variants.
Upon Table S1 ).
Whereas the RS cells comprised a relatively small proportion of the overall tumor cellularity in CHL cases, non-malignant cells-predominantly tissue macrophagescontributed to the total tumor cellularity and consistently demonstrated strong membranous staining for PD-L1 (Supplemental Table S1 ). We found that 19/25 (76%) cases of NSCHL, 7/8 (88%) cases of MCCHL, and 5/5 (100%) cases of CHL-NOS showed strong (2+ or 3+) membranous and/or cytoplasmic staining for PD-L1 in at least 20% of the total tumor cellularity, including non-malignant cells ( Figure 3B , Supplemental Table S1 ). Double immunostaining for PD-L1 and CD68 on a set of cases confirmed this analysis and revealed strong membranous PD-L1 staining of CD68+ macrophages in close proximity to PD-L1 positive RS cells (Figure 2A inset) . Only one case of NLPHL (7%) showed PD-L1 positive staining in 20% of the total tumor cellularity. However, malignant cells in this case were estimated to comprise 5% of the cellularity and only rare LP cells (~2%) were positive for PD-L1 ( Figure 3C and 3D, Supplemental Table S1 ). Overall, the expression of PD-L1 on the malignant tumor cells was well correlated with the expression of PD-L1 on the tumor infiltrating CD68+ macrophages in individual tumors (Supplemental Table S3 ).
We have previously shown that EBV-encoded LMP1 can promote PD-L1 expression in tumor cells. Table S1 ). Twenty of 29 (69%) Hodgkin lymphoma cases that were negative for EBV had malignant cells that scored positive for PD-L1 (Supplemental Table S1 ). Overall, EBV status did not predict a presence or absence of PD-L1 expression in Hodgkin lymphoma.
Two entities that lie on the histologic and genetic spectrum with CHL and NLPHL are PMBCL and TCHRBCL. Strong membranous PD-L1 expression was observed in 15/21 (71%) cases of PMBCL (90% median percent malignant cells, Figure 2C ) and 10/11 (91%) cases of TCHRBCL (10% median percent malignant cells, Figure 2D 
Expression of PD-L1 in EBV-and HHV8-positive malignancies.
Previously we reported a small series of EBV-positive PTLD cases that express PD-L1. 6 Using our newly characterized PD-L1 antibodies, we extended our analysis to include additional aggressive EBV-positive and -negative B-cell lymphomas (Table 1 Table S2 ). Six of 10 (60%) EBV-positive PTLD cases demonstrated strong PD-L1 membrane staining on at least 80% of malignant cells, consistent with our previous study (data not shown). 6 Four of 7 (57%) EBV-negative PTLD cases also showed strong membranous PD-L1 tumor staining ( Figure 4B ).
By contrast, only 7/66 (11%) EBV-negative DLBCL-NOS cases showed strong membranous PD-L1 tumor staining (range 10-90% of malignant cells) ( Figure 4C ). An additional 2 cases showed PD-L1 expression among the tumor infiltrating macrophages (Table 1 ). The median tumor composition for all of the DLBCL categories ranged from 70-90%.
A review of the clinical, pathological and molecular characteristics of the cases (14%) that scored as PD-L1 positive revealed that, of the 8 cases with available data, 7 cases were activated B-cell (ABC) type and 1 case was germinal center B-cell (GCB) type by the cell of origin (COO) classification scheme. In comparison to all DLBCL-NOS cases for which both the PD-L1 and COO status was known (61 cases total, 27 cases ABCtype, 23 cases GCB-type; 11 cases Type 3), the association between PD-L1 expression and the ABC-subtype was statistically significant (p=0.04, Fisher's exact test). Table S2 ). Careful morphologic review and double immunostaining for CD68 or PAX5 and PD-L1 (e. g. Figure 4A and 4B insets) were used to support our histologic assessment. As for the Hodgkin lymphomas, expression of PD-L1 by malignant cells and non-malignant tumor infiltrating macrophages was correlated (Supplemental Table S3 ).
PD-L1 expression on the variable numbers of non-malignant cells in EBV-
Analysis of additional EBV-and HHV8-positive malignancies showed that 4/9 (44%) PBL, 2/4 (50%) PEL, 4/6 (67%) ENKTCL, 16/18 (89%) NPC cases showed positive PD-L1 staining in malignant cells ( Figure 5 , Table 1, Supplemental Table S2 ). The majority of cases had greater than 50% malignant cells positive for PD-L1 and all cases in this group had at least 10% malignant cells positive for PD-L1. By contrast, no cases of EBV-positive BL or HHV8-positive KS were positive for PD-L1 ( Figure 5 , Table 1 ).
For cases with available tissue, we confirmed the patterns of PD-L1 expression obtained using the rabbit monoclonal antibody with those using the mouse monoclonal antibody.
We observed no differences in tumor staining between these two reagents ( Figure 5D and 5E insets; Supplemental Figure S2 ). Table S2 ). Although this pattern was observed with both anti-PD-L1 antibodies, it is unclear whether such staining represents exclusively cytoplasmic PD-L1 expression, or both cytoplasmic and low-level membrane expression.
In total, we observed robust PD-L1 expression by the malignant cells and tumor infiltrating macrophages in the majority of CHL, regardless of subtype and EBV-status, PMLBCL, TCRLBCL, EBV+ DLBCL, EBV+ and EBV-PTLD, HHV8+ PEL, and EBV+ NPC. We observed that nearly one-half of PBL and ENKTCL expressed PD-L1 as well. In contrast, only rare cases of NLPHL, DLBCL NOS, BL and no cases of KS expressed significantly detectable PD-L1 protein.
DISCUSSION
EBV-associated DLBCL, PTLD, ENKTCL, PBL, NPC, and HHV8-associated PEL are rare, but often aggressive, malignancies that are largely resistant to current chemotherapeutic regimens. [17] [18] [19] [20] [21] [22] Given their association with oncogenic viruses and with immunodeficiency, these tumors are attractive targets for immune-based therapies. In this analysis, we used a threshold of 5% positive staining of malignant cells to determine whether the tumors were scored as positive or negative for PD-L1. This threshold was selected to conform to the cut-point used in previous publications. 4, 15, 16 With this threshold, an association between cases scoring as positive for PD-L1 expression and clinical responsiveness to PD-1 immunotherapy in a small subset of cases has been reported. 4 However the antibody used to detect PD-L1 expression in that publication is distinct from those used here (and is not commercially available). Table S1 ).
PD-L1 expression is often driven by intrinsic genetic aberrations and disregulated signaling pathways within malignant cells. We have shown that RS cells of up to 40% of NSCHLs harbor amplification of 9p24.1, a genomic region that includes CD274, PDCD1LG2 (encoding PD-L2), and JAK2. 5 In cell lines, increased 9p24 copy number is associated with increased PD-L1 expression due to both direct amplification of CD274, and through increased JAK2 and enhanced JAK-STAT signaling. 6, 7 Additional, intrinsic mechanisms driving PD-L1 expression in the RS cells of CHL include EBV infection (32% of all CHL cases in this series) and constitutive AP1 activity. Similarly, approximately 70% of primary PMLBCLs also show gains in 9p24. 1, 5 and thus the robust PD-L1 protein expression we observe in the majority of PMLBCLs is likely attributable, in part, to this genetic lesion. Taken together, the percentage of CHL and PMLBCL with membranous PD-L1 on the malignant cells (87% and 71%, respectively) is consistent with these prior findings.
We have shown that EBV-transformed human B-cell lines (lymphoblastoid cell lines, LCLs) and EBV-positive PTLDs upregulate PD-L1. The results in the current study both confirm the PD-L1 protein expression by EBV-positive PTLDs using newly available, more robust antibodies and establish that the majority of additional EBV-associated malignancies express PD-L1, with the exception of BL.
In LCLs, PD-L1 induction is dependent upon constitutive signaling through the EBVencoded protein LMP1 via its effects on both the PD-L1 enhancer and promoter. 6 In both LCLs and EBV-positive PTLDs, EBV maintains a type III latency program characterized by expression of LMP1 in addition to LMP2A, the nuclear proteins EBNA-1, -2,-3 and -LP, and a series of non-coding RNAs (EBERs). 7, 12, 17 Similarly, in EBV-positive CHL, EBV maintains a type II latency program that is characterized by expression of LMP1, LMP2A, EBNA1, and EBERs. 23 In EBV-positive DLBCL, the virus maintains type II or type III latency program, 24 and suggesting that LMP1-mediated signaling is likely to directly contribute to tumorigenesis and to the immune evasion signature for these tumors.
In contrast, the virus in endemic BL resembles that of quiescent, EBV-infected memory B cells in immunocompetent hosts and is characterized by a minimal gene expression program that includes EBNA1 and EBERs, but not LMP1. 25 Consistent with a lack of signaling by EBV-encoded proteins in this tumor type, we found BL to be consistently negative for PD-L1. The EBV-encoded proteins, including LMP1, seem to be more heterogeneously expressed in ENKTCL and PBL than in EBV-positive PTLD, CHL, and DLBCL. 12, 20, 26 Therefore, the direct contribution of EBV-dependent and independent signaling pathways to the immune signature will require further analyses using cell culture models of these tumor types. Similarly, the contribution of viral-mediated signaling to expression of PD-L1 by NPC and PEL remains undefined. Surprisingly, we observed robust PD-L1 protein expression in EBV-negative PTLD.
Very little is known about this tumor type, which comprises up to 30% of post-transplant lymphoproliferative disorders. 27, 28 Because patients with these tumors can still respond to a reduction in immunosuppression, there is a likely role for immune surveillance in preventing or eradicating these tumors. In our cohort, EBV-negative PTLD was similar to EBV-positive PTLD in expressing PD-L1. Because we have shown that PD-L1 can be upregulated by mechanisms independently of viral-encoded gene products in EBVnegative CHL, we suggest that this tumor type is a good candidate for further genetic studies of the CD274 locus. Table S3 ).
Recently, it has been recognized that the number of tumor infiltrating macrophages in cases of CHL constitute a biomarker of inferior failure free survival and overall survival CHL. 8, 9 Several studies have since confirmed this observation. [30] [31] [32] [33] However, the biological basis for this association has remained undefined. PD-L1, as a major ligand for PD-1, serves to suppress T-cell immunity-including immunity directed towards virally-encoded antigens expressed in EBV-positive CHL. Given our development and validation of novel reagents for the detection of PD-L1 protein in FFPE tissue sections, it will be of interest to more broadly survey expression of this protein in additional hematological and non-hematological malignancies. Others have noted that PD-L1 is expressed by a subset of T-cell lymphoproliferative disorders, especially those at cutaneous sites. 29 In contrast, low grade B-cell lymphoproliferative disorders are thought to rarely express PD-L1. 35 Given our finding that PD-L1 expression can be limited to discrete and rare tumor types, it will be important to establish a comprehensive survey of hematological neoplasms based on detailed pathological classification. Moreover, it will be of interest to survey additional virus- The EBV-, HHV8-, and immunodeficiency-associated malignancies are uncommon but often aggressive, life-threatening neoplasms with limited treatment options. Our data indicate that PD-L1 expression is a common feature of these tumors. Among these tumors, EBV-positive DLBCL of the elderly is associated with a particularly dismal prognosis with a median survival of 2 years. 22 As this patient population is characterized by co-morbidities that complicate the use of standard chemotherapy, it is likely to be an ideal candidate for novel therapies that enhance anti-tumor immune responses. Although it will be important to interrogate larger tumor cohorts to confirm our findings, we suggest that clinical trials targeting PD-1 and PD-L1 may benefit patients with CHL, PMLBCL, TCHRBCL, EBV-positive DLBCL, PTLD, ENKTCL, PBL, PEL, and NPC may be appropriate candidates for clinical trials targeting the PD-1 pathway. E. F. Figure 5 
